73 related articles for article (PubMed ID: 7990854)
21. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
22. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Zimmerman TR; Sage JI; Lang AE; Mark MH
Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
[TBL] [Abstract][Full Text] [Related]
23. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
24. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
25. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
26. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
Gómez-Esteban JC; Zarranz JJ; Lezcano E; Velasco F; Ciordia R; Rouco I; Losada J; Bilbao I
Mov Disord; 2006 Jul; 21(7):983-8. PubMed ID: 16602112
[TBL] [Abstract][Full Text] [Related]
27. Parkinson's disease.
Clarke C; Moore AP
Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
[No Abstract] [Full Text] [Related]
28. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
[TBL] [Abstract][Full Text] [Related]
29. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Addy C; Assaid C; Hreniuk D; Stroh M; Xu Y; Herring WJ; Ellenbogen A; Jinnah HA; Kirby L; Leibowitz MT; Stewart RM; Tarsy D; Tetrud J; Stoch SA; Gottesdiener K; Wagner J
J Clin Pharmacol; 2009 Jul; 49(7):856-64. PubMed ID: 19491335
[TBL] [Abstract][Full Text] [Related]
30. Mesulergine: a dopamine agonist with novel properties in Parkinson's disease.
Lieberman AN; Gopinathan G; Pasternack P; Goldstein M
Adv Neurol; 1990; 53():533-7. PubMed ID: 1978521
[No Abstract] [Full Text] [Related]
31. Alteration of eating behaviors in patients with Parkinson's disease: possibly overlooked?
Miwa H; Kondo T
Neurocase; 2008; 14(6):480-4. PubMed ID: 19012168
[TBL] [Abstract][Full Text] [Related]
32. Relationship between brain levels of 3-(3-hydroxyphenyl)-N-n-propylpiperidine HCl enantiomers and effects on locomotor activity in rats.
Lundström J; Lindgren JE; Ahlenius S; Hillegaart V
J Pharmacol Exp Ther; 1992 Jul; 262(1):41-7. PubMed ID: 1352554
[TBL] [Abstract][Full Text] [Related]
33. [Modification of Parkinson tremor by budipine. A comparative study with amantadine].
Iizuka J; Fischer R
Nervenarzt; 1986 Mar; 57(3):184-6. PubMed ID: 3515215
[No Abstract] [Full Text] [Related]
34. Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
Kastin AJ; Barbeau A
Can Med Assoc J; 1972 Dec; 107(11):1079-81. PubMed ID: 4640811
[TBL] [Abstract][Full Text] [Related]
35. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia.
Lahti AC; Weiler MA; Corey PK; Lahti RA; Carlsson A; Tamminga CA
Biol Psychiatry; 1998 Jan; 43(1):2-11. PubMed ID: 9442338
[TBL] [Abstract][Full Text] [Related]
36. The search for selective dopaminergic autoreceptor agonists.
Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A; Nilsson JL
J Neural Transm Suppl; 1983; 18():131-7. PubMed ID: 6576112
[TBL] [Abstract][Full Text] [Related]
37. [Clinical aspects and follow-up of dopamine-induced psychoses in continuous dopaminergic therapy and their implications for the dopamine hypothesis of schizophrenic symptoms].
Heinz A; Przuntek H; Winterer G; Pietzcker A
Nervenarzt; 1995 Sep; 66(9):662-9. PubMed ID: 7477603
[TBL] [Abstract][Full Text] [Related]
38. Tremorlytic activity of budipine in Parkinson's disease.
Spieker S; Eisebitt R; Breit S; Przuntek H; Müller D; Klockgether T; Dichgans J
Clin Neuropharmacol; 1999; 22(2):115-9. PubMed ID: 10202609
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic effect of budipin in treating Parkinson's disease].
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):197-8. PubMed ID: 4075906
[No Abstract] [Full Text] [Related]
40. Efficacy of budipine and placebo in untreated patients with Parkinson's disease.
Müller T; Kuhn W; Przuntek H
J Neural Transm (Vienna); 2005 Aug; 112(8):1015-23. PubMed ID: 15583956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
